罕见的组织学前列腺癌亚型：癌症特异性和其他原因的死亡率。
Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality.
发表日期：2024 Jul 10
作者：
Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Stefano Puliatti, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Benedikt Hoeh, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz
来源：
PROSTATE CANCER AND PROSTATIC DISEASES
摘要：
为了评估罕见组织学前列腺癌亚型患者的癌症特异性死亡率 (CSM) 和其他原因死亡率 (OCM)。使用监测、流行病学和最终结果数据库（2004-2020），我们应用了平滑累积发病率图和竞争风险回归（CRR）模型。在 827,549 名患者中，1510 名（0.18%）患有导管癌，952 名（0.12%）患有神经内分泌癌，462 名（0.06%）患有粘液癌，95 名（0.01%）患有印戒细胞癌。在局部阶段，五年 CSM 与 OCM 发生率范围为：腺泡患者为 2% 对 10%，粘液癌患者为 3% 对 8%，神经内分泌癌患者为 55% 对 19%。在局部晚期阶段，腺泡患者的五年 CSM 与 OCM 发生率分别为 5% 和 6%，导管癌患者为 14% 和 16%，神经内分泌癌患者为 71% 和 15%。在转移阶段，五年 CSM 与 OCM 发生率范围为：印戒细胞癌为 49% 对 15%，粘液癌为 56% 对 16%，导管癌为 63% 对 9%，神经内分泌癌为 85% 对 12% 。在多变量 CRR 中，局部神经内分泌癌 (HR 3.09)、局部晚期神经内分泌癌 (HR 9.66)、局部晚期导管癌 (HR 2.26) 和最终转移性神经内分泌癌患者 (HR 3.57；所有 p<0.001) 相对于腺泡腺癌表现出更高的 CSM 率与腺泡腺癌相比，各期神经内分泌癌和局部晚期导管癌患者的 CSM 率更高。相反，粘液腺癌和印戒细胞腺癌的 CSM 率与腺泡腺癌的 CSM 率没有差异。© 2024。作者。
To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.Using the Surveillance, Epidemiology, and End Results database (2004-2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models.Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients.Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.© 2024. The Author(s).